File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Antiviral therapy for hepatitis B after kidney transplantation

TitleAntiviral therapy for hepatitis B after kidney transplantation
Authors
Issue Date2004
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/transproceed
Citation
8th Congress of the Asian-Society-of-Transplantation, Kualu Lumpur, Malaysia, 23-27 September 2003. In Transplantation Proceedings, 2004, v. 36 n. 7, p. 2124-2125 How to Cite?
AbstractThe clinical outcome of HBsAg-positive renal transplant recipients has been adversely affected by potentially fatal acute hepatitic exacerbations and chronic liver disease, in addition to the increased risk of hepatocellular carcinoma. The difficulty in predicting the evolution and severity of liver disease after kidney transplantation further confounds the management of these patients. The clinical course of HBsAg-positive renal transplant recipients can be modified favorably after nucleoside analogue therapy and quantitative HBV DNA assays have become available. The latter allow earlier detection of increased viral replication, before the onset of biochemical abnormality. We have combined serial HBV DNA monitoring with preemptive lamivudine therapy, and our results showed that this strategy markedly improved patient survival. Prolonged treatment, however, was associated with the selection of drug-resistant YMDDvariants. Hepatitic flares were common after the development of drug resistance and could lead to decompensation in a small proportion of patients. With careful selection, discontinuation of antiviral treatment was feasible in 18.5% of treated subjects. While the outcome of HBsAg-positive renal allograft recipients should continue to improve with the availability of more effective antiviral agents, financial constraints and the paucity of research data could hamper the optimal adoption of recent advances into clinical practice.
Persistent Identifierhttp://hdl.handle.net/10722/77633
ISSN
2015 Impact Factor: 0.867
2015 SCImago Journal Rankings: 0.455
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, TMen_HK
dc.date.accessioned2010-09-06T07:34:02Z-
dc.date.available2010-09-06T07:34:02Z-
dc.date.issued2004en_HK
dc.identifier.citation8th Congress of the Asian-Society-of-Transplantation, Kualu Lumpur, Malaysia, 23-27 September 2003. In Transplantation Proceedings, 2004, v. 36 n. 7, p. 2124-2125en_HK
dc.identifier.issn0041-1345en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77633-
dc.description.abstractThe clinical outcome of HBsAg-positive renal transplant recipients has been adversely affected by potentially fatal acute hepatitic exacerbations and chronic liver disease, in addition to the increased risk of hepatocellular carcinoma. The difficulty in predicting the evolution and severity of liver disease after kidney transplantation further confounds the management of these patients. The clinical course of HBsAg-positive renal transplant recipients can be modified favorably after nucleoside analogue therapy and quantitative HBV DNA assays have become available. The latter allow earlier detection of increased viral replication, before the onset of biochemical abnormality. We have combined serial HBV DNA monitoring with preemptive lamivudine therapy, and our results showed that this strategy markedly improved patient survival. Prolonged treatment, however, was associated with the selection of drug-resistant YMDDvariants. Hepatitic flares were common after the development of drug resistance and could lead to decompensation in a small proportion of patients. With careful selection, discontinuation of antiviral treatment was feasible in 18.5% of treated subjects. While the outcome of HBsAg-positive renal allograft recipients should continue to improve with the availability of more effective antiviral agents, financial constraints and the paucity of research data could hamper the optimal adoption of recent advances into clinical practice.en_HK
dc.languageengen_HK
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/transproceeden_HK
dc.relation.ispartofTransplantation Proceedingsen_HK
dc.rightsTransplantation Proceedings. Copyright © Elsevier Inc.en_HK
dc.subject.meshDNA, Viral - isolation & purificationen_HK
dc.subject.meshHepatitis B - prevention & controlen_HK
dc.subject.meshHepatitis B Surface Antigens - blooden_HK
dc.subject.meshHumansen_HK
dc.subject.meshKidney Transplantationen_HK
dc.subject.meshPostoperative Complications - prevention & control - virologyen_HK
dc.titleAntiviral therapy for hepatitis B after kidney transplantationen_HK
dc.typeConference_Paperen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0041-1345&volume=36&issue=7&spage=2124&epage=2125&date=2004&atitle=Antiviral+therapy+for+hepatitis+B+after+kidney+transplantationen_HK
dc.identifier.emailChan, TM:dtmchan@hku.hken_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.transproceed.2004.07.062en_HK
dc.identifier.pmid15518770-
dc.identifier.scopuseid_2-s2.0-7044269187en_HK
dc.identifier.hkuros99043en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-7044269187&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume36en_HK
dc.identifier.issue7en_HK
dc.identifier.spage2124en_HK
dc.identifier.epage2125en_HK
dc.identifier.isiWOS:000224772800094-
dc.publisher.placeUnited Statesen_HK
dc.description.other8th Congress of the Asian-Society-of-Transplantation, Kualu Lumpur, Malaysia, 23-27 September 2003. In Transplantation Proceedings, 2004, v. 36 n. 7, p. 2124-2125-
dc.identifier.scopusauthoridChan, TM=7402687700en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats